<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02135653</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 05813</org_study_id>
    <nct_id>NCT02135653</nct_id>
  </id_info>
  <brief_title>A Feasibility Study Followed By A Randomized Phase II Study Of Yoga For Radiation Therapy Side Effects In Prostate Cancer</brief_title>
  <official_title>A Feasibility Study Followed By A Randomized Phase II Study Of Yoga For Radiation Therapy Side Effects In Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will ascertain the feasibility and effect of Eischens yoga interventions on&#xD;
      radiation related fatigue, sexual dysfunction and urinary incontinence in stage I /II&#xD;
      prostate cancer patients undergoing radiotherapy with photons and/or protons without&#xD;
      prostatectomy. Subjects must be smoke free and have not taken regular yoga classes 6 months&#xD;
      prior to enrollment. Subjects will participate in twice weekly yoga sessions for 8 weeks and&#xD;
      complete 4 quality of life forms 5 times during study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The feasibility study refers to the ability to recruit patients willing to participate in the&#xD;
      Eischens yoga interventional arm. Those who are recruited during the feasibility study are&#xD;
      seemlessly move to the Phase II study, and for this reason the feasibility study and Eischens&#xD;
      yoga interventional arms are reported simply as the Eischens yoga interventional arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2013</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">May 24, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief Fatigue Inventory Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>A 9 item 11 point Likert-scale that rapidly assesses fatigue severity 0 - 90 range with greater numbers indicating greater levels of fatigue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Therapy: Physical Well-Being Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>7 item 5 point Likert-scale questionnaire. 0 - 35 range with larger number implies better physical well-being</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Therapy: Social Well-Being Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>7 item 5 point Likert-scale questionnaire. 0 - 35 range with larger number implies better social well-being</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Therapy: Emotional Well-Being Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>6 item 5 point Likert-scale questionnaire. 0 - 30 range with larger number implies better emotional well-being</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Therapy: Functional Well-Being</measure>
    <time_frame>8 weeks</time_frame>
    <description>7 item 5 point Likert-scale questionnaire. 0 - 35 range with larger number implies better functional well-being</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>5 item and 5 point Likert-scale The scores range from 0 to 25, with scores &gt;21 indicating normal erectile function and scores &lt;12 indicating moderate to severe ED</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Prostate Symptom Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>8 item 6 point Likert-scale Scores on this scale range from 0 to 35, with a score of 8 to 19 indicating moderate urinary symptoms and 20 to 35 severe urinary symptoms</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">68</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Feasibility Phase: Eischens Yoga Group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: Eischens Yoga Group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <arm_group_label>Feasibility Phase: Eischens Yoga Group</arm_group_label>
    <arm_group_label>Phase II: Eischens Yoga Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Eischens Yoga</intervention_name>
    <arm_group_label>Feasibility Phase: Eischens Yoga Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with stage I or II prostate cancer undergoing radiation therapy. Enrolled subjects&#xD;
        will not have smoked nor taken any regular yoga classes in the 6 months preceding their&#xD;
        participation in the study.&#xD;
&#xD;
        Additionally they will have not undergone a surgical prostatectomy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients&#xD;
&#xD;
          -  Prostate cancer patients undergoing active radiation therapy (external beam radiation&#xD;
             with photons and/ or protons). Prior or concurrent androgen deprivation therapy is&#xD;
             permitted.&#xD;
&#xD;
          -  Patients of age &gt;18 years, and all races will be included in the study.&#xD;
&#xD;
          -  Patients must have an ECOG Performance Score â‰¤ 1&#xD;
&#xD;
          -  All patients must sign an informed consent form&#xD;
&#xD;
        Caregivers&#xD;
&#xD;
          -  Subject is age &gt;18 years&#xD;
&#xD;
          -  Subject is English-speaking&#xD;
&#xD;
          -  Subject must sign an informed consent form&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Patients&#xD;
&#xD;
          -  Patients with medical restrictions that may interfere with or prevent them from taking&#xD;
             part in the yoga interventions per their physician orders as evaluated by ECOG&#xD;
             Performance Status score.&#xD;
&#xD;
          -  Active, regular cigarette smokers, such that smoking may interfere with relaxation and&#xD;
             breathing modalities of the yoga interventions. (Smokers that have been smoke-free for&#xD;
             6 months may be included)&#xD;
&#xD;
          -  Patients who currently practice or have recently practiced yoga (taken a yoga class on&#xD;
             a regular basis in the last 6 months).&#xD;
&#xD;
          -  Patients who are undergoing chemotherapy for any reason&#xD;
&#xD;
          -  Patients with evidence of metastatic disease&#xD;
&#xD;
        Caregivers&#xD;
&#xD;
          -  Subjects that are unwilling or unable to provide informed consent&#xD;
&#xD;
          -  Subjects with medical restrictions that may interfere with or prevent them from taking&#xD;
             part in the yoga interventions&#xD;
&#xD;
          -  Active, regular cigarette smokers, such that smoking may interfere with relaxation and&#xD;
             breathing modalities of the yoga interventions. (Smokers that have been smoke-free for&#xD;
             6 months may be included)&#xD;
&#xD;
          -  Patients who currently practice or have recently practiced yoga (taken a yoga class on&#xD;
             a regular basis in the last 6 months).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neha Vapiwala, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 2, 2014</study_first_submitted>
  <study_first_submitted_qc>May 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2014</study_first_posted>
  <results_first_submitted>May 18, 2020</results_first_submitted>
  <results_first_submitted_qc>April 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 19, 2021</results_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 24, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT02135653/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Feasibility Phase and Phase II: Radiotherapy and Eischens Yoga have been combined because the feasibility phase's purpose was to identify and recruit patients willing to participate in the Phase II: Radiotherapy and Eischens Yoga. Those in the feasibility are seamlessly enrolled in the Phase II: Radiotherapy and Eischens Yoga.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Feasibility/Phase II: Radiotherapy and Eischens Yoga</title>
          <description>Radiotherapy and Eischens Yoga</description>
        </group>
        <group group_id="P2">
          <title>Phase II: Radiotherapy Without Eischens Yoga</title>
          <description>Radiotherapy without Eischens Yoga</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Feasibility Phase and Phase II: Radiotherapy and Eischens Yoga have been combined because the feasibility phase's purpose was to identify and recruit patients willing to participate in the Phase II: Radiotherapy and Eischens Yoga. Those in the feasibility are seamlessly enrolled in the Phase II: Radiotherapy and Eischens Yoga</population>
      <group_list>
        <group group_id="B1">
          <title>Feasibility/Phase II: Radiotherapy and Eischens Yoga</title>
          <description>Radiotherapy and Eischens Yoga</description>
        </group>
        <group group_id="B2">
          <title>Phase II: Radiotherapy Without Eischens Yoga</title>
          <description>Radiotherapy without Eischens Yoga</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.1" spread="6.7"/>
                    <measurement group_id="B2" value="72.8" spread="7.0"/>
                    <measurement group_id="B3" value="72.08" spread="6.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Feasibility/Phase II: Radiotherapy and Eischens Yoga</title>
            <description>Radiotherapy with Eischens Yoga</description>
          </group>
          <group group_id="O2">
            <title>Phase II: Radiotherapy Without Eischens Yoga</title>
            <description>Radiotherapy without Eischens Yoga</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Fatigue Inventory Score</title>
        <description>A 9 item 11 point Likert-scale that rapidly assesses fatigue severity 0 - 90 range with greater numbers indicating greater levels of fatigue</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Feasibility/Phase II: Radiotherapy and Eischens Yoga</title>
            <description>Radiotherapy with Eischens Yoga</description>
          </group>
          <group group_id="O2">
            <title>Phase II: Radiotherapy Without Eischens Yoga</title>
            <description>Radiotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Fatigue Inventory Score</title>
          <description>A 9 item 11 point Likert-scale that rapidly assesses fatigue severity 0 - 90 range with greater numbers indicating greater levels of fatigue</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="16.3"/>
                    <measurement group_id="O2" value="27.4" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessment of Cancer Therapy: Physical Well-Being Score</title>
        <description>7 item 5 point Likert-scale questionnaire. 0 - 35 range with larger number implies better physical well-being</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Feasibility/Phase II: Radiotherapy and Eischens Yoga</title>
            <description>Radiotherapy with Eischens Yoga</description>
          </group>
          <group group_id="O2">
            <title>Phase II: Radiotherapy Without Eischens Yoga</title>
            <description>Radiotherapy&#xD;
Without Eischens Yoga</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Cancer Therapy: Physical Well-Being Score</title>
          <description>7 item 5 point Likert-scale questionnaire. 0 - 35 range with larger number implies better physical well-being</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.9" spread="2.3"/>
                    <measurement group_id="O2" value="24.3" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessment of Cancer Therapy: Social Well-Being Score</title>
        <description>7 item 5 point Likert-scale questionnaire. 0 - 35 range with larger number implies better social well-being</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Feasibility/Phase II: Radiotherapy and Eischens Yoga</title>
            <description>Radiotherapy with Eischens Yoga</description>
          </group>
          <group group_id="O2">
            <title>Phase II: Radiotherapy Without Eischens Yoga</title>
            <description>Radiotherapy without Eischens Yoga</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Cancer Therapy: Social Well-Being Score</title>
          <description>7 item 5 point Likert-scale questionnaire. 0 - 35 range with larger number implies better social well-being</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5" spread="2.1"/>
                    <measurement group_id="O2" value="21.4" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessment of Cancer Therapy: Emotional Well-Being Score</title>
        <description>6 item 5 point Likert-scale questionnaire. 0 - 30 range with larger number implies better emotional well-being</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Feasibility/Phase II: Radiotherapy and Eischens Yoga</title>
            <description>Radiotherapy with Eischens Yoga</description>
          </group>
          <group group_id="O2">
            <title>Phase II: Radiotherapy Without Eischens Yoga</title>
            <description>Radiotherapy without Eischens Yoga</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Cancer Therapy: Emotional Well-Being Score</title>
          <description>6 item 5 point Likert-scale questionnaire. 0 - 30 range with larger number implies better emotional well-being</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" spread="3.4"/>
                    <measurement group_id="O2" value="21.0" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessment of Cancer Therapy: Functional Well-Being</title>
        <description>7 item 5 point Likert-scale questionnaire. 0 - 35 range with larger number implies better functional well-being</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Feasibility/Phase II: Radiotherapy and Eischens Yoga</title>
            <description>Radiotherapy with Eischens Yoga</description>
          </group>
          <group group_id="O2">
            <title>Phase II: Radiotherapy Without Eischens Yoga</title>
            <description>Radiotherapy without Eischens Yoga</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Cancer Therapy: Functional Well-Being</title>
          <description>7 item 5 point Likert-scale questionnaire. 0 - 35 range with larger number implies better functional well-being</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" spread="4.8"/>
                    <measurement group_id="O2" value="21.4" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>International Index of Erectile Function Score</title>
        <description>5 item and 5 point Likert-scale The scores range from 0 to 25, with scores &gt;21 indicating normal erectile function and scores &lt;12 indicating moderate to severe ED</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Feasibility/Phase II: Radiotherapy and Eischens Yoga</title>
            <description>Radiotherapy with Eischens Yoga</description>
          </group>
          <group group_id="O2">
            <title>Phase II: Radiotherapy Without Eischens Yoga</title>
            <description>Radiotherapy without Eischens Yoga</description>
          </group>
        </group_list>
        <measure>
          <title>International Index of Erectile Function Score</title>
          <description>5 item and 5 point Likert-scale The scores range from 0 to 25, with scores &gt;21 indicating normal erectile function and scores &lt;12 indicating moderate to severe ED</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" spread="4.8"/>
                    <measurement group_id="O2" value="21.4" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>International Prostate Symptom Score</title>
        <description>8 item 6 point Likert-scale Scores on this scale range from 0 to 35, with a score of 8 to 19 indicating moderate urinary symptoms and 20 to 35 severe urinary symptoms</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Feasibility/Phase II: Radiotherapy and Eischens Yoga</title>
            <description>Radiotherapy with Eischens Yoga</description>
          </group>
          <group group_id="O2">
            <title>Phase II: Radiotherapy Without Eischens Yoga</title>
            <description>Radiotherapy without Eischens Yoga</description>
          </group>
        </group_list>
        <measure>
          <title>International Prostate Symptom Score</title>
          <description>8 item 6 point Likert-scale Scores on this scale range from 0 to 35, with a score of 8 to 19 indicating moderate urinary symptoms and 20 to 35 severe urinary symptoms</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="8.1"/>
                    <measurement group_id="O2" value="15" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 Weeks</time_frame>
      <desc>Feasibility Phase and Phase II: Yoga Group have been combined because the feasibility phase's purpose was to identify and recruit patients willing to participate in the Phase II: Yoga Group. Those in the feasibility are seamlessly enrolled in the Phase II: Yoga Group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Feasibility/Phase II: Radiotherapy and Eischens Yoga</title>
          <description>Radiotherapy and Eischens Yoga</description>
        </group>
        <group group_id="E2">
          <title>Phase II: Radiotherapy Wihtout Eischens Yoga</title>
          <description>Radiotherapy without Eischens Yoga</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Neha Vapiwala</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>(215) 662-2337</phone>
      <email>Neha.Vapiwala@pennmedicine.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

